Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study
Denosumab appears to be effective in pediatric FD/MAS patients, however safety concerns remain. Comprehensive pre-treatment evaluation and close monitoring throughout the treatment course are essential. Further prospective studies and randomized controlled trials are needed to determine optimal dosing strategies and establish long-term safety in this population.
Authors
- W. Qi
- Qianqian Pang (ORCID: https://orcid.org/0000-0002-4028-5560)
- Li Mei
- Ruizhi Jiajue
- Ruotong Zhou
- Yiyi Gong
- Lijia Cui
- Yan Jiang
- Weibo Xia
- Xiaoping Xing
- Xiang Li
- Ou Wang
- Yue Chi
- Quanshi Ouyang
- Wei Liu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.3389/fendo.2026.1762370
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Peking Union Medical College Hospital
- National Science and Technology Major Project